OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Editorial introductions	116
The sounds of silencing: dynamic epigenetic control of HIV latency	79
Future options for long-acting HIV treatment and prevention	37
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	32
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	31
Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research	29
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	27
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	27
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	26
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	26
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	26
Harnessing natural killer cells to target HIV-1 persistence	26
Editorial introduction	24
Editorial introduction	22
Editorial introduction	21
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	21
Persistent elite controllers as the key model to identify permanent HIV remission	18
New latency-promoting agents for a block-and-lock functional cure strategy	18
Loneliness and social isolation in people with HIV	18
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	18
Challenges towards an AIDS-free generation in Africa and Asia	15
Pulse check: modern strategies for cardiovascular risk in women with detection and prevention in women with HIV	14
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	14
Estrogen depletion and immune activation and inflammation in women with HIV	14
Defining multimorbidity in people with HIV – what matters most?	14

Public health surveillance and outbreak preparedness for mpox	14
Balancing polypharmacy and comorbidity management: cardiovascular health	14
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	13
Integrating substance use services into HIV care: an underused implementation science opportunity	13
Stigma as a facilitator of the 2022 mpox outbreak	13
Impact of coronavirus disease 2019 on co-morbidities in HIV	13
Role of follicular homing natural killer cells in HIV infection	13
The origins of new SARS-COV-2 variants in immunocompromised individuals	13
Editorial introduction	13
Viral and immune predictors of HIV posttreatment control	13
Mpox and the impact on people with HIV	12
New vector and vaccine platforms: mRNA, DNA, viral vectors	12
Aging of adult lifetime survivors with perinatal HIV	12
The multifaceted nature of HIV tissue reservoirs	12
Beyond criminalization: reconsidering HIV criminalization in an era of reform	11
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	11
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
Obesity among women with HIV	11
Gender and sex considerations in HIV and bone health	11
Metabolic dysfunction-associated steatotic liver disease in people with HIV	11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	10
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	10
Roadmap for spatial transcriptomics of HIV in tissues	10
HIV and cardiovascular disease: the role of inflammation	9
Editorial: New drugs for HIV: quo vadis?	9
The severity of COVID-19 across the spectrum of HIV	9
Host factors predisposing to kidney disease in people with HIV	9
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	9
Maintain the gains: methods to evaluate the sustainability and scalability of HIV-related prevention, care, and treatment programs	9
Use of implementation theories, models, and frameworks in PrEP implementation research from 2022–2025: innovation and participation	9
Strategies to target the central nervous system HIV reservoir	8
Persistent HIV-1 transcription during ART: time to reassess its significance?	8
Editorial introductions	8
Editorial introduction	8
HIV drug resistance in various body compartments	8
Innovative models of care supporting people aging with HIV	8
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	8
Contemporary issues in gynecologic and reproductive health for women with HIV	7
Causes and outcomes of hepatic fibrosis in persons living with HIV	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	7
The pathogenesis of obesity in people living with HIV	7
HIV-1 subtypes and latent reservoirs	6
Editorial introductions	6
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
Editorial: Is it time to implement injectable antiretroviral treatments globally?	6
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	6
Whole person HIV services: a social science approach	6
Editorial introductions	6
Hepatitis C elimination in people with HIV: progress, gaps, and future directions	6

Scaling up preexposure prophylaxis to maximize HIV prevention impact	5
Human papillomavirus infection among adolescents living with HIV: a focus on prevention	5
The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure	5
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	5
Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review	5
Single cell analyses of the HIV reservoir in the CNS and CSF: recent insights and implications	5
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	5
Towards an HIV cure: one cell at a time	5
Editorial introductions	5
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	5
The innovative use of qualitative and mixed methods research to advance improvements along the HIV prevention and care continua	5
Editorial introductions	5
Care of people aging with HIV in resource limited settings	5
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	5
Role of islatravir in HIV treatment and prevention: an update	5
Towards a molecular profile of antiretroviral therapy-free HIV remission	5
Cognitive impairment in persons with HIV: changing aetiologies and management strategies	4
Humanized mice for studying HIV latency and potentially its eradication	4
The state of the art of adaptation strategies for HIV-related interventions	4
Delivery platforms for broadly neutralizing antibodies	4
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	4
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	4
An evidence-based call for tailored interventions to support women with HIV who use substances	4
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	4
Cardiovascular disease risk in women living with HIV	4
Editorial introductions	4
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults	4
Targeting HIV myeloid and central nervous system reservoirs for HIV cure	4
Zika virus: an overview update	3
Pediatric immunotherapy and HIV control	3
Using single cell technologies to understand HIV latency models	3
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection	3
The future of long-acting agents for preexposure prophylaxis	3
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	3
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	3
Monocytes across life span in HIV infection: lights and shadows	3
Editorial introduction	3
Management of pain and other palliative needs in older people with HIV	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	3
The female microbiome in HIV prevention, pathogenesis, and treatment	3
Editorial introduction	3
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	3
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	3
HIV T-cell immunogen design and delivery	3
Post-intervention control in HIV immunotherapy trials	3
The power of ten in HIV remission: insights from hematopoietic stem cell transplantation	3
Utilizing immunotherapy towards achieving a functional cure for HIV-1	2
Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention	2
HIV and obesity: updates in management strategies	2
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	2
Stepping stones to cure in children with HIV	2
Long-acting preexposure prophylaxis: early data on roll-out in the United States	2
HIV cure: an acceptability scientific agenda	2
Preventing perinatal HIV acquisition; current gaps and future perspectives	2
Humoral immunity in HIV-1 post-treatment controllers	2
Pulmonary comorbidities in people with HIV− the microbiome connection	2
Editorial introductions	2
Geriatric syndromes in women living with HIV	2
Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic	2
Editorial introductions	2
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	2
Cardiovascular health in people with perinatally acquired HIV – where do we stand?	2
Elite controllers microbiome: unraveling the mystery of association and causation	2
Promises and challenges: cabotegravir for preexposure prophylaxis	2
Mycobacterium tuberculosis in HIV co-infection: a growing concern in Europe?	2
Understanding residual risk of cardiovascular disease in people with HIV	2
The vaginal microbiome and HIV transmission dynamics	2
Implementation of long-acting antiretroviral therapy in low-income and middle-income countries	2
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	2
Modeling the fallout: projecting the global impact of donor funding cuts on HIV prevention, treatment, and care	2
Technologies for HIV-1 drug resistance testing: inventory and needs	2
Barriers and facilitators related to COVID-19 vaccine acceptance and uptake among people living with HIV	2
Long-acting preexposure prophylaxis in low- and middle-income countries: key considerations for implementation	2
Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV	2